Items where authors include "Genge, A."

Article

Allen, M.D., Van eijk, R.P.A. orcid.org/0000-0002-7132-5967, Knox, L. orcid.org/0000-0003-2545-1046 et al. (7 more authors) (2025) Variability across versions of the self-administered ALSFRS-R: a review and call for harmonization. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. ISSN 2167-8421

Hewamadduma, C., Freimer, M., Genge, A. et al. (8 more authors) (2025) Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. Journal of Neurology, 272 (7). 457. ISSN 0340-5354

van den Berg, L.H., Rothstein, J.D., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (26 more authors) (2024) Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. The Lancet Neurology, 23 (9). pp. 901-912. ISSN 1474-4422

Genge, A., Cedarbaum, J.M., Shefner, J. et al. (19 more authors) (2024) The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25 (3-4). pp. 382-387. ISSN 2167-8421

Howard, J.F. orcid.org/0000-0002-7136-8617, Bresch, S., Farmakidis, C. et al. (24 more authors) (2024) Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Therapeutic Advances in Neurological Disorders, 17. ISSN 1756-2864

Gwathmey, K.G. orcid.org/0000-0002-7589-8826, Corcia, P., McDermott, C.J. orcid.org/0000-0002-1269-9053 et al. (4 more authors) (2023) Diagnostic delay in amyotrophic lateral sclerosis. European Journal of Neurology, 30 (9). pp. 2595-2601. ISSN 1351-5101

Miller, T.M., Cudkowicz, M.E., Genge, A. et al. (23 more authors) (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387 (12). pp. 1099-1110. ISSN 0028-4793

Shaw, P. orcid.org/0000-0002-8925-2567, Miller, T., Cudkowicz, M. et al. (7 more authors) (2022) Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results. Journal of Neurology, Neurosurgery & Psychiatry, 93 (9). e2. ISSN 0022-3050

van Eijk, R.P.A., Beelen, A., Kruitwagen, E.T. et al. (16 more authors) (2021) A road map for remote digital health technology for motor neuron disease. Journal of Medical Internet Research, 23 (9). e28766. ISSN 1438-8871

Miller, T., Cudkowicz, M., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (28 more authors) (2020) Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383 (2). pp. 109-119. ISSN 0028-4793

van den Berg, L.H., Sorenson, E., Gronseth, G. et al. (20 more authors) (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 92 (14). e1610-e1623. ISSN 0028-3878